The Stockholm unit can handle biosafety level 2/2+ and BSL 3 organisms. Credit: Valneva SE.

NorthX Biologics has acquired Valneva’s clinical trial manufacturing unit in Stockholm, Sweden.

The takeover comprises the transfer of a multi-purpose site with 30 staff, located in the Stockholm life sciences cluster.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The staff and facility have a long history of experience in internal services, contractual development and production activities with external clients. 

Their capabilities in mammalian expression systems and viral vectors complement the expertise of NorthX’s existing business of sophisticated microbial-based protein and plasmid deoxyribonucleic acid (DNA) production. 

The acquired unit possesses expertise in process development, GMP manufacturing, ramp-up, quality assurance/release and control analytics. It can also handle biosafety level (BSL) 2/2+ and BSL 3 organisms. 

This acquisition will support NorthX in bolstering its expertise and providing complete services to a global client base.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Valneva Sweden managing director Janet Hoogstraate will become part of NorthX following the deal’s closure. 

NorthX Biologics chairman Thomas Eldered stated: “This strategic move marks a significant milestone in our growth journey and strengthens NorthX as Sweden’s innovation hub. 

“We are now able to work with ATMPs and advanced biologics, including process development and manufacture for clinical trials and commercial requirements.”